<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>Summit Therapeutics</title>
    <link>https://www.biospace.com/employer/541321/summit-therapeutics</link>
    <description>Summit Therapeutics</description>
    <language>en-US</language>
    <lastBuildDate>Tue, 11 Feb 2020 04:34:22 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/541321/summit-therapeutics.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma</title>
      <link>https://www.biospace.com/summit-therapeutics-to-receive-1-0-million-milestone-payment-from-eurofarma</link>
      <description>Summit Therapeutics plc announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratórios SA.</description>
      <pubDate>Tue, 11 Feb 2020 04:34:22 GMT</pubDate>
      <guid>https://www.biospace.com/summit-therapeutics-to-receive-1-0-million-milestone-payment-from-eurofarma</guid>
    </item>
    <item>
      <title>BioSpace Movers &amp; Shakers, Feb. 28</title>
      <link>https://www.biospace.com/biospace-movers-and-shakers-feb-28</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>Biopharma and life sciences strengthen their executive leadership teams and boards with this week's Movers &amp; Shakers.</description>
      <pubDate>Thu, 27 Feb 2020 17:48:33 GMT</pubDate>
      <guid>https://www.biospace.com/biospace-movers-and-shakers-feb-28</guid>
    </item>
    <item>
      <title>BioSpace Movers &amp; Shakers, April 17</title>
      <link>https://www.biospace.com/biospace-movers-and-shakers-april-17</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>Pharma and life sciences companies boost their executive ranks and boards with this week's Movers &amp; Shakers.</description>
      <pubDate>Thu, 16 Apr 2020 16:39:12 GMT</pubDate>
      <guid>https://www.biospace.com/biospace-movers-and-shakers-april-17</guid>
    </item>
    <item>
      <title>Win Some, Lose Some: Clinical Trial Updates</title>
      <link>https://www.biospace.com/you-win-some-you-lose-some-clinical-trial-updates</link>
      <dc:creator>Mark Terry</dc:creator>
      <description>After last week’s avalanche of clinical trial news associated with the American Society of Hematology Annual Meeting, there are far fewer announcements, but some companies are getting their news out ahead of the holidays.</description>
      <pubDate>Tue, 21 Dec 2021 13:46:55 GMT</pubDate>
      <guid>https://www.biospace.com/you-win-some-you-lose-some-clinical-trial-updates</guid>
    </item>
    <item>
      <title>Pfizer Fails in C.diff, BMS Announces Priority Review for Opdivo in NSCLC</title>
      <link>https://www.biospace.com/three-large-pharma-companies-share-updates-on-phase-iii-clinical-trials</link>
      <dc:creator>Hannah Chudleigh</dc:creator>
      <description>Pfizer's Clostridioides difficile infection vaccine failed to hit the mark, BMS announced priority review for Opdivo in resectable Non-Small Cell Lung Cancer, and Saol enlists help from GeneDx.</description>
      <pubDate>Tue, 01 Mar 2022 15:34:57 GMT</pubDate>
      <guid>https://www.biospace.com/three-large-pharma-companies-share-updates-on-phase-iii-clinical-trials</guid>
    </item>
    <item>
      <title>A New Quarter Brings New CEOs for Summit and vTv</title>
      <link>https://www.biospace.com/new-ceos-for-summit-therapeutics-and-vtv-therapeutics</link>
      <dc:creator>Jazmine Colatriano, M.S.</dc:creator>
      <description>Summit Therapeutics Inc. announced that Dr. Maky Zangenah, DDS, has been named co-Chief Executive Officer, and Paul Sekhri has risen to the title of CEO at vTv Therapeutics.</description>
      <pubDate>Wed, 27 Jul 2022 13:05:32 GMT</pubDate>
      <guid>https://www.biospace.com/new-ceos-for-summit-therapeutics-and-vtv-therapeutics</guid>
    </item>
    <item>
      <title>Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work</title>
      <link>https://www.biospace.com/summit-announces-barda-expands-ridinilazole-award-by-8-8-million-to-include-additional-nda-enabling-work</link>
      <description>Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that the Biomedical Advanced Research and Development Authority (‘BARDA’) has expanded its award for the clinical and regulatory development of Summit’s precision antibiotic ridinilazole for the treatment of C. difficile infection (‘CDI’) by $8.8 million.</description>
      <pubDate>Mon, 27 Jan 2020 23:06:42 GMT</pubDate>
      <guid>https://www.biospace.com/summit-announces-barda-expands-ridinilazole-award-by-8-8-million-to-include-additional-nda-enabling-work</guid>
    </item>
    <item>
      <title>Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering</title>
      <link>https://www.biospace.com/summit-therapeutics-rights-offering-nearing-expiration-date-robert-w-duggan-declares-intention-to-fully-oversubscribe-in-the-rights-offering</link>
      <description>Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight Time on May 10, 2021 (the “Expiration Date”)</description>
      <pubDate>Wed, 05 May 2021 16:56:03 GMT</pubDate>
      <guid>https://www.biospace.com/summit-therapeutics-rights-offering-nearing-expiration-date-robert-w-duggan-declares-intention-to-fully-oversubscribe-in-the-rights-offering</guid>
    </item>
    <item>
      <title>Summit Therapeutics Publishes Scientific Updates to Corporate Website</title>
      <link>https://www.biospace.com/summit-therapeutics-publishes-scientific-updates-to-corporate-website</link>
      <description>Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that we have updated the scientific and related content on our corporate website with respect to our investigational drug, ridinilazole, which is currently enrolling patients in its Phase 3 clinical trials.</description>
      <pubDate>Thu, 06 May 2021 12:06:05 GMT</pubDate>
      <guid>https://www.biospace.com/summit-therapeutics-publishes-scientific-updates-to-corporate-website</guid>
    </item>
    <item>
      <title>Summit Therapeutics Announces Closing of $75 Million Rights Offering</title>
      <link>https://www.biospace.com/summit-therapeutics-announces-closing-of-75-million-rights-offering</link>
      <description>Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results.</description>
      <pubDate>Wed, 12 May 2021 19:06:03 GMT</pubDate>
      <guid>https://www.biospace.com/summit-therapeutics-announces-closing-of-75-million-rights-offering</guid>
    </item>
  </channel>
</rss>
